Applied Genetic Tech drops in concert with Spark in response to gene therapy study

• Thinly-traded small cap Applied Genetic Technologies (AGTC -15.5%) slumps on on more than 2x normal volume, albeit on turnover of only 200K shares. Certain gene therapy companies are under pressure today in response to a study that showed the benefits of therapy waned after three years.
• Previously: Spark Therapeutics off 11% premarket on data showing benefits of gene therapy fail to persist (May 4)